Aclarion shares surge 12.85% premarket after partnering with Source Healthcare to expand Nociscan availability and generate real-world evidence.

Aclarion surged 12.85% in premarket trading following the announcement of a partnership with Source Healthcare, a Los Angeles-based orthopedic and regenerative health clinic, to expand access to its Nociscan diagnostic platform. The collaboration, led by interventional pain management specialist Dr. Timothy T. Davis, aims to generate real-world evidence comparing Nociscan’s non-invasive biomarker analysis to anesthetic discography, a spinal injection diagnostic procedure. The agreement reinforces Nociscan’s scalability and clinical validation, with Aclarion highlighting its 97% surgical success rate when treating discs identified by the technology. The move aligns with the company’s growth strategy to strengthen data assets for payer and provider adoption, positioning Nociscan as a non-invasive alternative in chronic low back pain management.